Lavipharm S.A. (ATSE:LAVI) signing of an asset purchase agreement to acquire Lonarid N and Lonalgal from Boehringer Ingelheim International GmbH on December 1, 2023. The transaction will be financed by the company?s own funds. The products are commercially available in the Greek market and are expected to be marketed by Lavipharm during the first quarter of 2024 upon completion of the relevant product marketing authorizations?

transfer. Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with the intention to commercialize them internationally. The historical total sales of the two pharmaceutical products amount to ?8 million.

Sales by Lavipharm to take place during Q2-24.